GlassScriptPhysician profile
Angela M Klawitter
NPI 1639481088
$12,352.66
in general payments reported to CMS, 2019-2025
50 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $1,550 · 2021: $1,980 · 2022: $1,970 · 2023: $2,170 · 2024: $1,805 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,330 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,330.19 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,735.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,462.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,403.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $976.22 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $775.23 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $741.82 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $529.57 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $521.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $508.37 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.83 | 2019-2025 | Xifaxan, Trulance |
| Corium, LLC | $446.55 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $267.09 | 2019-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $257.65 | 2019-2023 | Belsomra, Steglatro, Dificid |
| Astellas Pharma US INC | $218.13 | 2020-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $208.31 | 2023-2025 | Rexulti |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Klawitter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.